Ann: Neuren and Acadia expand global partnership for trofinetide, page-32

First 32 Last

Share
Profile

Follow
good1234

2,896 Posts.

506

14/07/23

10:42

Post #: 68785283
Share

Originally posted by kmsmith: ↑

All sounds fabulous - Management have always been pretty special. What I am slightly unsure about is the last line -

Neuren has an obligation not to develop .... any product ..... for North America in an indication for which Acadia develops trofinitide, except for Phelan-McDermind, Pitt Hopkins, Angelman and Prader Willis syndromes.

A number of years ago (and I am sure it remains the case) it was suggested Trof / 2591 may help a whole range of 'indications'- Autism / MS / TBI .. maybe even Parkinsons (from memory).

Sounds like Acadia can develop for one (or a number) of these and Neuren would thus be excluded. Cannot imagine Acadia could afford to seriously develop too many indications at once, but would like to know how this is designed operate. Dare say the fine print will be all-important, but would like to hear more at some stage.

All the best to investors and potential users.

Expand

I asked this question a while back and the consensus view was that there are plenty of indications that can be developed where no overlap will occur.

The partnership between NEU and Acadia has just been strengthened, so I reckon they can work out a win win approach to further development.

Last edited by good1234: 14/07/23

NEU Price at posting: $13.43 Sentiment: Hold Disclosure: Held
11 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Open: Oz shares to see out tumultuous FY24-25 with green day | June 30

First 32 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $14.20		Change 0.890(6.69%)		Mkt cap ! $1.761B

Open	High	Low	Value	Volume
$13.50	$14.26	$12.96	$9.111M	655.8K

Buyers (Bids)

No.	Vol.	Price($)
1	2000	$14.17

Sellers (Offers)

Price($)	Vol.	No.
$14.23	3278	1

View Market Depth

No.	Vol.	Price($)
1	1300	14.030
1	500	14.000
1	357	13.970
1	30	13.900
1	700	13.700

Price($)	Vol.	No.
14.260	2920	1
14.300	1000	1
14.380	72	1
14.400	1000	1
14.460	434	1

Last trade - 16.15pm 27/06/2025 (20 minute delay)

NEU (ASX) Chart

Ann: Neuren and Acadia expand global partnership for trofinetide, page-32

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Open: Oz shares to see out tumultuous FY24-25 with green day | June 30

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Neuren and Acadia expand global partnership for trofinetide, page-32

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Australia’s gas crisis is here – and dying coal plants aren’t helping

ASX Market Open: Oz shares to see out tumultuous FY24-25 with green day | June 30

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News